The National Medical Products Administration approved the marketing of velaglucerase beta for injection
May 19, 2025
Source: drugdu
95
On May 15, the National Medical Products Administration approved the marketing of velaglucerase beta for injection (trade name: Gorenin) applied by Beihai Kangcheng (Shanghai) Biotechnology Co., Ltd. through the priority review and approval procedure. It is suitable for long-term enzyme replacement therapy for adolescents and adults with type I and type III Gaucher disease aged 12 and above. Gaucher disease is an autosomal recessive metabolic disease caused by functional defects of glucocerebrosidase in lysosomes and is included in the "First List of Rare Diseases". Velaglucerase beta for injection can reduce the storage of glucocerebroside in the body, thereby exerting a therapeutic effect. The listing of this variety provides a new treatment option for related patients.
网址：https://finance.eastmoney.com/a/202505153405858055.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Which Strength Training Method Is Best for You? Experts Break Down the Options July 9, 2025
- Is One Type of Water Healthier Than Another? Here’s What Experts Say July 9, 2025
- Innovent Biologics’ Suvicitamab is approved for marketing, solving the dilemma in the treatment of platinum-resistant ovarian cancer July 7, 2025
- Everest Medicines’ Next-Generation BTK Inhibitor EVER001 Announces Latest Clinical Results, Continues to Demonstrate Efficacy and Safety July 7, 2025
- Jinsai Pharmaceutical’s Fuxin Qibaimab was approved, reducing the risk of gout recurrence by 87% in half a year July 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
